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Background: To investigate the effects of dipeptidyl peptidase-4 inhibitor (DPP4i) as add-on medications to metformin on pro-
gression of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus, compared with sulfonylurea (SU) or thiazolidine-
dione (TZD).
Methods: We identified 4,447 patients with DPP4i, 6,136 with SU, and 617 with TZD in addition to metformin therapy from the 
database of Korean National Health Insurance Service between January 2013 and December 2015. Cox proportional hazards re-
gression models were used to calculate hazard ratios (HRs) for DR progression. The progression of DR was defined by the proce-
dure code of panretinal photocoagulation, intravitreal injection or vitrectomy; or the addition of diagnostic code of vitreous hem-
orrhage, retinal detachment, or neovascular glaucoma.
Results: The age and sex-adjusted HR of DR progression was 0.74 for DPP4i add-on group compared with SU add-on group 
(95% confidence interval [CI], 0.62 to 0.89). This lower risk of DR progression remained significant after additional adjustments 
for comorbidities, duration of metformin therapy, intravitreal injections and calendar index year (HR, 0.80; 95% CI, 0.66 to 0.97). 
Conclusion: This population-based cohort study showed that the use of DPP4i as add-on therapy to metformin did not increase 
the risk of DR progression compared to SU. 
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INTRODUCTION
Diabetic retinopathy (DR) is the most frequent microvascular 
complication of diabetes, leading to severe visual impairment 
in working-age population [1]. Retinal neovascularization and 
its accompanying complications such as vitreous hemorrhage 
and neovascular glaucoma occurring in proliferative stage, as 
well as diabetic edema, contribute to major sources of severe 
visual loss in DR [1,2]. These late-stage complications require 
treatments as laser photocoagulation or intravitreal injections 
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of anti-vascular endothelial growth factor agents or corticoste-
roids, which need repeated treatments and result in high so-
cioeconomic burden [3-5]. 
Metformin is commonly used antidiabetic drug as first-line 
therapy in United States as well as in Korea [6-8]. Sulfonylurea 
(SU) still remains the most commonly prescribed second-line 
agent, while the use of dipeptidyl peptidase-4 inhibitor (DP-
P4i) increased significantly over the past decade [6-8]. DPP4i 
have introduced at the end of 2008 in Korea and approved by 
the Ministry of Food and Drug Safety in 2012 [9], and their 
prescription has been increased to be 4-fold in 2013 (38.4% of 
total antidiabetic prescription) compared to 2009 [6]. The anti-
diabetic effect of DPP4i is based on the glucose-lowering activ-
ities of the gastrointestinal hormone, glucagon-like peptide-1 
[10]. DPP4i seems to be protective in cardiovascular events as 
well as in nephropathy through previous studies [10-13], while 
few investigations have been performed on retinopathy. 
We previously investigated the effect of DPP4i to the pro-
gression of DR as a pilot study, showing that DPP4i had pro-
tective effect on DR progression independently from glucose-
lowering effect [14]. However, there are controversies concern-
ing the effect of DPP4i in DR [15-17], which highlight further 
investigation for safety issue associated with DR and DPP4i. 
Accordingly, we investigated the risk of DR progression associ-
ated with DPP4i use based on real-world population-cohort 
study. 
METHODS
Study design and participants
The study protocol was reviewed and approved by the Institu-
tional Review Board of Severance Hospital at Yonsei University 
College of Medicine (IRB No. 4-2016-1005) and informed 
consent was waived because of the anonymous nature of the 
data. Data of approximately 50 million of Korean patients cov-
ered by the mandatory social National Health Insurance Ser-
vice (NHIS) was investigated. The NHIS involves claim data-
base including demographic information, diagnoses, prescrip-
tions, and procedures. Diagnoses are coded using the Interna-
tional Classification of Diseases, 10th revision (ICD-10). The 
NHIS also requires all insured employees and self-employed 
individuals aged ≥40 years as well as their family dependents 
for general medical examination regularly every 2 years. This 
health screening data include body size, blood pressure, blood 
chemistry data including lipid profile, health behaviors, and 
personal and family histories of diseases. We used the NHIS 
database for primary analysis, and secondary analysis implied 
the health screening data of NHIS. 
This study used NHIS data (NHIS-2017-1-054) made by 
NHIS of Korea. We first extracted patients with type 2 diabetes 
mellitus (E11 to E14, ICD-10 codes) who had received metfor-
min monotherapy for at least 90 days between January 2009 
and December 2012. The second line antidiabetic medications 
implied DPP4i, SU, or thiazolidinedione (TZD), and those ini-
tiated second line antidiabetic therapy from January 2013 to 
December 2015 were included. Patients treated with above 
mentioned medications for more than 90 consecutive days 
were included, while those with insulin treatment were exclud-
ed. Further inclusion and exclusion criteria are summarized in 
Fig. 1.
Outcomes and covariates
The presence of DR was determined on the diagnostic code of 
DR (H36.0, ICD-10 code). Among the patients already diag-
nosed with DR, the progression of DR was defined by (1) the 
procedure code of panretinal photocoagulation (S5160), intra-
vitreal injection (S5070) or vitrectomy (S5160 and S5121-22); 
or (2) the addition of diagnostic code of vitreous hemorrhage 
(H43.1 and H45.0, ICD-10 codes), retinal detachment (H33.0, 
H33.4, and H33.5, ICD-10 codes), or neovascular glaucoma 
(H40.5 and H40.88, ICD-10 codes). The definition of DR pro-
gression was based on the protocol of the Diabetic Retinopathy 
Clinical Research Network [18]. 
Following covariates were subjected to serial statistical ad-
justments to minimize confounding effects: age, sex, duration 
of metformin therapy, hypertension, dyslipidemia, atrial fibril-
lation, chronic kidney disease, microvascular complications of 
diabetes (neuropathy, or nephropathy), the Charlson comor-
bidity score, intravitreal injections, and calendar index year. 
The Charlson comorbidity score is a weighted index that im-
plies the number and the seriousness of comorbid disease, 
used to predict survival in patients with multiple comorbidities 
[19]. The calendar index year was used to adjust selection bias 
associated with calendar time for cohort studies [20]. 
Statistical analysis
All analysis were performed using SAS software version 9.4 
(SAS Institute Inc., Cary, NC, USA). Baseline characteristics 
were compared among DPP4i users, SU users, and TZD users 
as second line medication. Cox proportional hazards regres-
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sion models were used to calculate hazard ratios (HRs) and 
95% confidence intervals (CIs) for DR progression. Potential 
confounders were sequentially adjusted in two statistical mod-
els as follows: model 1, age and sex; model 2, age, sex, duration 
of metformin therapy, the Charlson comorbidity score, intra-
vitreal injections, calendar index year, and comorbidities (hy-
pertension, dyslipidemia, atrial fibrillation, chronic kidney 
disease, and microvascular complications of diabetes). 
For the analysis of the subgroup with health screening data, 
model 2 was adjusted for age, sex, duration of metformin ther-
apy, body mass index, waist circumference, systolic blood pres-
sure, total cholesterol, high density lipoprotein cholesterol, low 
density lipoprotein cholesterol, triglycerides, fasting glucose, 
serum creatinine level, smoking status, family history of stroke 
and heart disease, the Charlson comorbidity score, intravitreal 
injections, and calendar index year. 
 
RESULTS
Among patients with DR who used second line drug along 
with metformin, those using DPP4i finally implied 4,447 pa-
tients, those with SU were 6,136 patients, and those with TZD 
Approximately, 50 million Korean patients in the
National Health Insurance Service Database
397,147 Patients with type 2 diabetes mellitus 
treated with MET from January 1, 2009, to  
December 31, 2012
Excluded
76,758 Patients who had received MET 
monotherapy <90 days
Excluded
113,171 Patients who had continued  
MET monotherapy
44,225 Patients who had received  
second-line antidiabetic therapy other 
than the studied regimens
45,885 Patients who had received  
second-line therapy <90 days
725 Patients aged <30 years or >90 years 
at index date
320,389 Patients started MET monotherapy  
for ≥90 days from January 1, 2009, to  
December 31, 2012
116,383 Patients prescribed second-line therapy  
(index date) for ≥90 days after  
December 31, 2012
11,200 Patients with diabetic  
retinopathy
MET+DPP4i
(n=6,136)
MET+SU
(n=4,447)
MET+TZD
(n=617)
Fig. 1. Flow chart of the study design. MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazoli-
dinedione. 
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Table 2. Hazard ratios for aggravation of diabetic retinopathy by type of second-line antidiabetic medication
Drugs PY No. of cases Event rate, /100,000 PY
Adjusted 1a Adjusted 2b
HR (95% CI) P value HR (95% CI) P value
MET+SU 7,087 3,271 46,154 1.00 1.00
MET+DPP4i 7,835 4,217 53,823 0.74 (0.62–0.89) 0.001 0.80 (0.66–0.97) 0.024
MET+TZD 948 399 42,089 0.45 (0.27–0.76) 0.003 0.50 (0.29–0.84) 0.009
PY, person-years; HR, hazard ratio; CI, confidence interval; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, 
thiazolidinedione. 
aAdjusted for sex and age, bAdjusted for sex, age, duration of metformin therapy, hypertension, dyslipidemia, atrial fibrillation, chronic kidney 
disease, microvascular complications of diabetes (neuropathy, or nephropathy), the Charlson comorbidity score, intravitreal injections, and cal-
endar index year.
were 617 patients (Fig. 1). The mean age of the study population 
was 59.3±10.6 years, and 47.4% were male. Baseline character-
istics of these patients are presented in Table 1. 
The age and sex-adjusted HR of DR progression was 0.74 
(95% CI, 0.62 to 0.89; P=0.001) for DPP4i add-on group com-
pared with SU add-on group (Table 2). This lower risk of DR 
progression remained significant after additional adjustments 
for comorbidities, duration of metformin therapy, intravitreal 
injections and calendar index year (HR, 0.80; 95% CI, 0.66 to 
0.97; P=0.024). 
To adjust other confounding risk factors, we performed a 
subgroup analysis with additional adjustment for variables in-
vestigated at the health screening data of NHIS including fast-
ing glucose level. Baseline characteristics of this subgroup are 
summarized in Supplementary Table 1. DPP4i add-on therapy 
was still associated with lower risk of DR progression although 
not statistically significant (HR, 0.89; 95% CI, 0.64 to 1.24; P= 
0.493) (Table 3). 
Table 1. Baseline characteristics by type of second-line antidiabetic medication
Variable MET+SU (n=4,447) MET+DPP4i (n=6,136) MET+TZD (n=617) P value
Age, yr 61.1±10.6 58.1±10.5 58.1±10.5 <0.001
Men, sex 2,064 (46.4) 2,927 (47.7) 323 (52.4) 0.018
Duration of MET monotherapy, mo 10.1±3.5 10.3±3.6 10.2±3.6 0.002
Duration of second line therapy, mo 20.3±17.2 19.7±15.7 18.6±16.5 <0.001
Comorbidities
   Hypertension 3,166 (71.2) 4,124 (67.2) 410 (66.5) <0.001
   Dyslipidemia 3,155 (71.0) 5,029 (82.0) 482 (78.1) <0.001
   Atrial fibrillation 67 (1.5) 108 (1.8) 10 (1.6) 0.599
   Chronic kidney disease 59 (1.3) 65 (1.1) 6 (1.0) 0.405
   Diabetic neuropathy 652 (14.7) 877 (14.3) 69 (11.2) 0.068
   Diabetic nephropathy 328 (7.4) 662 (10.8) 72 (11.7) <0.001
Charlson score, unit 3.3±1.8 3.2±1.7 3.2±1.7 0.072
Intravitreal injection 46 (1.0) 60 (1.0) 3 (0.5) 0.429
Inclusion year <0.001
   2009 2,120 (47.7) 3,079 (50.2) 355 (57.5)
   2010 1,113 (25.0) 1,547 (25.2) 128 (20.8)
   2011 685 (15.4) 899 (14.7) 84 (13.6)
   2012 529 (11.9) 611 (10.0) 50 (8.1)
Values are presented as mean±standard deviation or number (%).
MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione.
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DISCUSSION
In this study, less patients with DPP4i revealed DR progression 
than those with SU as add-on therapy. We previously reported 
a retrospective pilot study showing the protective effect of DP-
P4i on DR progression based on Early Treatment Diabetic 
Retinopathy Study (ETDRS) severity scale, which was inde-
pendent of glycemic control [14,21]. This study showed similar 
protective tendency, while the determination of DR progres-
sion was based on procedures required to treat complications 
or diagnoses associated with proliferative stage [18], not by the 
ETDRS severity scale. As the codes for procedures are manda-
torily submitted in NHIS, less requirement of procedure codes 
with DPP4i use might reflect benefits for patients by less costs 
and saved time for treatment.
However, this protective effect of DPP4i was not evident in 
the subgroup analysis performed with those with available 
health screening data. The lower HR of DR progression with 
DPP4i was not statistically significant after adjusting variables 
including fasting glucose levels. It should be noted that the 
fasting glucose level was slightly higher in SU add-on group in 
Supplementary Table 1. Based on these data, there is a possibil-
ity that the benefit using DPP4i over SU in DR progression as 
shown in Table 1 might be due to better glycemic control since 
the glycemic control is important in DR progression [22]. A 
recent cohort study revealed that DPP4i did not increased 
overall risk of DR while a risk existed at early treatment phase, 
comparing ever-use and never-use cases of DPP4i [23]. Simi-
larly, a cohort study with United States population aged 65 
years or older reported that DPP4i use did not increase the risk 
of DR requiring treatments [24]. Taken together, it is reason-
able to conclude that the use of DPP4i may not increase the 
risk of DR progression, compared to SU as add-on medication 
to metformin. DPP4i can be considered as second-line therapy 
in patient with type 2 diabetes mellitus, in safety from DR pro-
gression.
DR is one of major causes of visual impairment resulting in 
an important burden on health care systems [25-27], so that 
protective factors other than glycemic control need to be con-
sidered in clinical practice. Retinopathy and nephropathy 
share common pathogenesis as microvascular complications 
of diabetes [12]. Renoprotective effect of DPP4i has been re-
ported [28-30], while there are few clinical studies on the effect 
of retinopathy [14]. Experimental studies on DR and DPP4i 
have revealed conflicting results. One study using linagliptin 
reported that loss of pericytes and retinal ganglion cells were 
prevented with the medication [16], while another study with 
sitagliptin also reported inhibition of blood-retinal barrier 
breakdown as well as decreased retinal inflammation and neu-
ronal apoptosis [31]. Topical administration of DPP4i showed 
also protective effect by preventing neurodegeneration as well 
as vascular leakage in experimental diabetic retina [32]. How-
ever, there is still a study reporting increased vascular leakage 
with DPP4i suggesting possibility of DR progression [15]. 
Relatively small number of patients with TZD were included 
in this study compared to those with DPP4i or SU, which 
might be associated with low rate of TZD prescription in Ko-
rea [6]. Anti-angiogenic and anti-inflammatory effects of TZD 
in ischemic retina have been reported in experimental studies 
[33,34], while a recent cohort study revealed no consistent evi-
dence of DR progression in patients with TZD suggesting no 
association [35]. The low HR of DR aggravation in patients 
with TZD shown in this study was not further discussed here 
to avoid misinterpretation of the results, which need to be in-
Table 3. Hazard ratios for aggravation of diabetic retinopathy by type of second-line antidiabetic medication in a subgroup with 
available health screening data
Drugs PY No. of cases Event rate, /100,000 PY
Adjusted 1a Adjusted 2b
HR (95% CI) P value HR (95% CI) P value
MET+SU 2,436 1,106 45,402 1.00 1.00
MET+DPP4i 3,065 1,630 53,181 0.89 (0.64–1.24) 0.493 0.92 (0.64–1.32) 0.646
MET+TZD 315 146 46,349 0.36 (0.11–1.13) 0.079 0.38 (0.12–1.22) 0.103
PY, person-years; HR, hazard ratio; CI, confidence interval; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, 
thiazolidinedione. 
aAdjusted for sex and age, bAdjusted for sex, age, duration of metformin therapy, body mass index, waist circumference, systolic blood pressure, 
total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, fasting glucose, serum creatinine level, 
smoking status, and family history of stroke and heart disease, the Charlson comorbidity score, intravitreal injections, and calendar index year.
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vestigated with larger sample size of patients with TZD.
There are several limitations in this study. First, the presence 
of DR was defined by the presence of diagnostic code from 
NHIS database. Although the diagnostic code is mandatory 
for any patient, the accuracy of diagnoses are not adjudicated 
by medical records or laboratory tests. Second, bevacizumab is 
one of the widely used treatment for diabetic macular edema 
or complications of proliferative DR [36,37], but intravitreal 
injection of bevacizumab was not identified in this analysis as 
this procedure is not covered by NHIS due to its off-label use 
in Korea. However, the ratio of patients treated intravitreally 
with other medications (ranibizumab, aflibercept, triamcino-
lone, or dexamethasone implants) were not different between 
groups, so that intravitreal bevacizumab injections may be also 
similar between groups as this may not be one-sided. Third, 
lack of glycemic control data is also critical, as intensive glyce-
mia treatment and intensive combination treatment of dyslip-
idemia are well known to reduce the rate of DR aggravation 
[22]. We tried to overcome this limitation by adjusting fasting 
glucose levels instead in our subgroup analysis, although insuf-
ficient to reflect the whole study population. Lastly, follow-up 
period for DR aggravation was relatively short to compare the 
effect for second-line antidiabetic medications. However, 
above mentioned limitations might affect both DPP4i group 
and SU group, so that one-sided application might be prevent-
ed. Further study with larger sample size of patients with blood 
chemistry data would be helpful, so that more criteria would 
be available for the choice of second-line antidiabetic medica-
tions. 
In conclusion, this population-based cohort study demon-
strated that the use of DPP4i as second line medication did not 
increase the risk of DR progression compared with SU in pa-
tients with DR. This suggests that DPP4i can be considered as 
second line antidiabetic medication safely in patients with DR.
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Supplementary Table 1. Baseline characteristics of second-line drugs in a subgroup with available health screening data
Variable MET+SU (n=1,504) MET+DPP4i (n=2,384) MET+TZD (n=224) P value
Age, yr 59.9±10.0 57.0±9.7 57.3±9.5 <0.001
Men, sex 736 (48.9) 1,198 (50.3) 123 (54.9) 0.234
Duration of MET treatment, mo 10.1±3.5 10.3±3.5 10.0±3.5 0.104
Duration of second line therapy, mo 20.4±16.8 20.2±16.0 19.3±16.9 0.040
Body mass index, kg/m2 25.0±3.3 24.9±3.1 24.7±3.0 0.401
Waist circumference, cm 84.9±8.5 84.2±8.4 83.6±8.1 0.012
Systolic blood pressure, mm Hg 128.6±14.7 126.1±14.5 127.2±14.8 <0.001
Total cholesterol, mg/dL 186.7±39.4 177.8±36.1 177.7±35.2 <0.001
Triglyceride, mg/dL 134.5 (98.0–189.0) 124.0 (90.0–176.0) 132.0 (92.5–187.0) 0.001
HDL-C, mg/dL 51.4±20.9 51.4±23.0 50.0±12.2 0.645
LDL-C, mg/dL 106.0±50.1 99.9±57.6 97.6±31.6 0.001
Fasting glucose, mg/dL 132.0 (115.0–152.5) 126.0 (113.0–142.0) 123.5 (112.0–142.0) <0.001
Creatinine, mg/dL 1.01±1.01 0.98±0.99 1.04±1.07 0.528
Smoking status 0.383
   Never 978 (65.0) 1,550 (65.0) 137 (61.2)
   Former 322 (21.4) 517 (21.7) 61 (27.2)
   Current 204 (13.6) 317 (13.3) 26 (11.6)
Family history
   Stroke 125 (8.3) 262 (11.0) 24 (10.7) 0.024
   Heart disease 69 (4.6) 143 (6.0) 11 (4.9) 0.157
Charlson score, unit 3.1±1.7 3.1±1.6 3.1±1.7 0.851
Intravitreal injection 13 (0.9) 20 (0.8) 0 (0.0) 0.382
Inclusion year <0.001
   2009 665 (44.2) 1,181 (49.5) 133 (59.4)
   2010 390 (25.9) 631 (26.5) 46 (20.5)
   2011 265 (17.6) 349 (14.6) 33 (14.7)
   2012 184 (12.2) 223 (9.4) 12 (5.4)
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; TZD, thiazolidinedione; HDL-C, high density lipoprotein choles-
terol; LDL-C, low density lipoprotein cholesterol. 
